FFI-Ventures joins Partex.AI

One partner for the drug lifecycle. Precision AI at scale.

We are delighted to announce that FFI Ventures is joining Partex.AI, a partnership built on a shared conviction and delivering opportunity for life science companies. Precision AI, combined with deep scientific and commercial expertise, fundamentally changes how therapies develop and reach patients.

Together, we become the first fully integrated, end-to-end AI partner for life science companies. FFI’s proven expertise in medical affairs, regulatory, pharmacovigilance, and commercial strategy combines with Partex.AI’s industry-leading AI infrastructure, biomedical knowledge graph, and drug discovery capabilities to create a partnership that covers the entire drug development lifecycle.

Benefits for Pharma, Biotech, Medtech

Life science companies have long had to manage fragmented vendor relationships, with separate partners for discovery, regulatory, medical, and commercial. Each transition between stages creates delays, discontinuities, and lost context. Most AI vendors in the industry are consulting firms or point solutions, strong in one area but unable to connect the dots across the full lifecycle. FFI and Partex.AI combined enable a different solution: deep biomedical and real-world evidence data and infrastructure, a fully integrated AI technology platform, and the strategic and executive expertise to deliver real outcomes.

1. Transform R&D, clinical development, customer engagement, licensing with precision AI

Clients accelerate innovation and knowledge work, building on a track record of reducing effort by 35-83% and shortening processes by up to 86%. More than 75 companies have entered value sharing and business partnerships and the licensing pipeline available includes more than 40 products. In-house wet lab to rapidly confirm hypotheses and profile molecules.

2. Deep industry expertise, track record of delivering results

Executive and operational leaders with deep hands-on experience across more than 40 therapy areas. 3 oncology therapeutic assets in the Partex pipeline. More than 2.2 million patient records for real world data analyses. 186 patents granted and 321 filed.

3. Capacity & in-house capabilities across geographies and the expertise to scale rapidly

Flexible resourcing and locations, with more than 200 staff in Germany, Switzerland, GCC countries, India, US, Singapore. More than 400 hospital and lab partnerships in Europe, Asia and the US. More than 1000 NVIDIA DGX H100s GPUs.

Next

Great partnerships are rarely just about capability; they are about people who share a vision of the future and choose to build it together.

FFI and Partex.AI will push the boundaries of precision AI to create value for life science clients, from the early stages of discovery to the successful completion of therapy by patients. We are one team now. And we are just getting started.

Contact us at info@ffi-ventures.com.